SWK — Investor Presentation (April 2020)
32 slides from SWK's investor presentation, Apr 20, 2020
Slide 1: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing
Slide 2: Forward-looking and Cautionary Statements
Forward - looking and Cautionary Statements 2 Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu
Slide 3: SWK Holdings - Overview
• SWK targets $5mm to $20mm financings, a market niche that is largely ignored by larger market participants and generates attractive full - cycle returns • Business focus is secured financings and royalty monetizations, but will selectively consider equity - like opportunities and M&A Underserved,
Slide 4: SWK Holdings - Segments
SWK Holdings - Segments 4 SWK operates through two segments: Life Science Specialty Finance and Enteris BioPharma Centered on SWK’s core focus on monetizing revenue streams and Intellectual Property LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic
Slide 5: Life Science Finance Opportunity
Life Science Finance Opportunity 5 Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/midsized life science cos - Few participants exist for sub - $20mm life science financings Life science products are highly portable - Approved & market
Slide 6: Value Creation Strategy
Value Creation Strategy 6 Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other upside features to enhance return profile Evaluate and pursue
Slide 7: Book Value Components
Book Value Components 7 Tangible Finance Book Value / Share = $14.74 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma • In August, 2019, SWK paid $21.5 million up
Slide 8: Corporate Milestones
Corporate Milestones Pre - 2014 2014 2015 2016 2017 2018 2019 2020 • Predecessor Kana Software assets sold to Kay Technologies; $450mm+ NOLs remained at sale • Winston Black and Brett Pope hired to launch life science technology finance strategy • $113mm raised through private placement and rights o
Slide 9: Financing Segment Portfolio Overview: 4Q19
Financing Segment Portfolio Overview: 4Q19 * Finance receivables plus marketable investments ** Private warrants carried at zero cost/not valued on balance sheet *** Updated for publicly announced fundings and expirations from 12/31/19 through 3/30/20 • Income Producing Assets * : $175.1mm • Finance
Slide 10: Financial Snapshot
Financial Snapshot * Defined as finance receivables, marketable investments, and investment in unconsolidated entity less non - controlling interes ts ** Eliminates provision for income taxes, Enteris intangibles amortization, and non - cash mark - to - market changes on warrant assets and equity se
Slide 11: Financing Strategy
Financing Strategy 11 SWK Targets Low - to - Mid Teens Effective Yields 4Q19 Effective Yield of 13.2% * Finance receivables plus marketable investment; Includes non - accruals ** Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition po
Slide 12: Current Structured Credit Portfolio
Current Structured Credit Portfolio 12 Eton Pharmaceuticals 11.14.19 $10 million – Structured Credit Misonix 9.27.19 $30 million – Structured Credit
Slide 13: Current Royalty Portfolio
Current Royalty Portfolio 13
Slide 14: Portfolio Realizations
Portfolio Realizations As of December 31, 2019 SWK has exited 17 financings for a total 1.2x CoC return and 20% weighted average IRR ̶ 14 resulted in positive realizations with a cumulative 1.4x CoC and weighted average 32% IRR ̶ SynCardia position was sold to distressed private equity firm with SWK
Slide 15: Portfolio Realizations to Strategic Buyers
Portfolio Realizations to Strategic Buyers Ten realizations to strategic buyers demonstrated a median 30% LTV of SWK’s original loan value Seven of the ten businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology 15 $ in mm Target Buyer Closing
Slide 16: Sourcing
Sourcing SWK has a well - developed and diversified sourcing network ̶ SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $20mm financings From 2017 -
Slide 17: Structured Debt and Royalties
• Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Structured Debt • Compan
Slide 18: Value Proposition to Partners
Value Proposition to Partners • Smaller companies often don’t have financial profile to qualify for traditional financing sources • Companies in this niche often have few options outside of a dilutive equity raise • The IPO market is largely closed to companies of this size requiring expensive and d
Slide 19: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 19 • Opiant is a publicly traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant needed capital to pursue
Slide 20: Historical Financing: Galil Medical
Historical Financing: Galil Medical 20 • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force OPPORTUNITY SOLUTION • In
Slide 21: Enteris BioPharma Acquisition Rationale
• Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly - owned portfolio of milestones and royalties on IP - protected biotherapeutics with substantial ups
Slide 22: Proven Technology, Late-Stage Commercial Partnerships, and Internal Pipeline
Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline 21 Drug Delivery Technology • Peptelligence technology allows for oral delivery of drugs that are typically injected, including peptides and BCS class II, III, and IV small molecules • Extensive intellectual property esta
Slide 23: Enteris Acquisition Terms
$21.5mm paid upfront to acquire 100% of Enteris’ capital stock Proceeds from Cara Therapeutics licensing agreement, which includes milestone payments and low - single digit royalties on sales o f Oral Korsuva™: ̶ Seller will receive 100% of $8.0mm upfront payment ̶ SWK will receive 60% of the first
Slide 24: Leadership Team
Leadership Team Winston Black Chief Executive Officer • Appointed CEO in 2016 • Co - founded PBS Capital Management • Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications Charles Jacobsen Chief Financial Officer • Appointed CFO in 2012 • Curre
Slide 25: SWK - Rapidly-Growing Life Science Focused Specialty Finance Company
Custom financing solutions for commercial - stage healthcare companies and royalty owners Targeting $5mm to $20mm financings, a niche that is largely ignored by larger market participants Focus is secured financings and royalty monetizations, but will selectively consider equity - like opportunities
Slide 26: Balance Sheet
Balance Sheet 26 $ in 000s Dec-19 Dec-18 Dec-17 Dec-16 ASSETS Cash and cash equivalents 11,158$ 20,227$ 30,557$ 32,182$ Interest and accounts receivable, net 2,554 2,195 1,637 1,054 Marketable investments 1,802 - 1,856 2,621 Other current assets 1,087 138 126 240 Total current assets 16,601$ 22,560$
Slide 27: Income Statement
Income Statement 27 $ in 000s, except per share amounts Dec-19 Dec-18 Dec-17 Dec-16 Revenues Finance receivable interest income, including fees 30,117$ 25,978$ 26,877$ 15,747$ Pharmaceutical development 621 - - - Marketable investments interest income - - - 92 Income related to investments in uncons
Slide 28: Cash Flow Statement
Cash Flow Statement 28 $ in 000s,* Dec-19 Dec-18 Dec-17 Dec-16 Cash flows from operating activities: Consolidated net income $23,828 $6,195 $8,251 $32,041 Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entity - - (10,530) (
Slide 29: Reconciliation of Non-GAAP Adjusted Net Income
Reconciliation of Non - GAAP Adjusted Net Income 29 The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas
Slide 30: Reconciliation of Non-GAAP Adjusted Net Income
Reconciliation of Non - GAAP Adjusted Net Income 30 The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods denoted below
Slide 31: Contact Information
Contact Information 31 Winston Black: ̶ Phone: 972.687.7251 ̶ Email: wblack@swkhold.com Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com Office address: ̶ 14755 Preston Road, Ste 105 Dallas, TX 75254 Website: www.swkhold.com
Slide 32: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing